<?xml version="1.0" encoding="utf-8"?>
<Return xmlns="http://www.irs.gov/efile" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.irs.gov/efile" returnVersion="2022v5.0">
  <ReturnHeader binaryAttachmentCnt="0">
    <ReturnTs>2023-11-14T13:16:21-06:00</ReturnTs>
    <TaxPeriodEndDt>2022-12-31</TaxPeriodEndDt>
    <PreparerFirmGrp>
      <PreparerFirmEIN>331197384</PreparerFirmEIN>
      <PreparerFirmName>
        <BusinessNameLine1Txt>ANDERSEN TAX LLC</BusinessNameLine1Txt>
      </PreparerFirmName>
      <PreparerUSAddress>
        <AddressLine1Txt>350 SOUTH GRAND AVE STE 2000</AddressLine1Txt>
        <CityNm>LOS ANGELES</CityNm>
        <StateAbbreviationCd>CA</StateAbbreviationCd>
        <ZIPCd>90071</ZIPCd>
      </PreparerUSAddress>
    </PreparerFirmGrp>
    <ReturnTypeCd>990PF</ReturnTypeCd>
    <TaxPeriodBeginDt>2022-01-01</TaxPeriodBeginDt>
    <Filer>
      <EIN>854224393</EIN>
      <BusinessName>
        <BusinessNameLine1Txt>TORREY COAST FOUNDATION</BusinessNameLine1Txt>
      </BusinessName>
      <BusinessNameControlTxt>TORR</BusinessNameControlTxt>
      <USAddress>
        <AddressLine1Txt>5930 CORNERSTONE COURT WEST 300</AddressLine1Txt>
        <CityNm>SAN DIEGO</CityNm>
        <StateAbbreviationCd>CA</StateAbbreviationCd>
        <ZIPCd>92121</ZIPCd>
      </USAddress>
    </Filer>
    <BusinessOfficerGrp>
      <PersonNm>ALAN BRAYNIN</PersonNm>
      <PersonTitleTxt>PRESIDENT</PersonTitleTxt>
      <SignatureDt>2023-11-14</SignatureDt>
      <DiscussWithPaidPreparerInd>1</DiscussWithPaidPreparerInd>
    </BusinessOfficerGrp>
    <SigningOfficerGrp>
      <PersonFullName>
        <PersonFirstNm>ALAN</PersonFirstNm>
        <PersonLastNm>BRAYNIN</PersonLastNm>
      </PersonFullName>
      <SSN>999009999</SSN>
    </SigningOfficerGrp>
    <IRSResponsiblePrtyInfoCurrInd>0</IRSResponsiblePrtyInfoCurrInd>
    <PreparerPersonGrp>
      <PreparerPersonNm>DONGWHAN KIM</PreparerPersonNm>
      <PTIN>P02052783</PTIN>
      <PhoneNum>2135932300</PhoneNum>
    </PreparerPersonGrp>
    <AdditionalFilerInformation>
      <TrustedCustomerGrp>
        <TrustedCustomerCd>0</TrustedCustomerCd>
        <AuthenticationAssuranceLevelCd>AAL1</AuthenticationAssuranceLevelCd>
        <IdentityAssuranceLevelCd>IAL1</IdentityAssuranceLevelCd>
      </TrustedCustomerGrp>
    </AdditionalFilerInformation>
    <TaxYr>2022</TaxYr>
    <BuildTS>2023-04-26 12:10:37Z</BuildTS>
  </ReturnHeader>
  <ReturnData documentCnt="8">
    <IRS990PF documentId="RetDoc1235000001">
      <Organization501c3ExemptPFInd>X</Organization501c3ExemptPFInd>
      <FMVAssetsEOYAmt>303352893</FMVAssetsEOYAmt>
      <MethodOfAccountingAccrualInd>X</MethodOfAccountingAccrualInd>
      <AnalysisOfRevenueAndExpenses>
        <ContriRcvdRevAndExpnssAmt>305010000</ContriRcvdRevAndExpnssAmt>
        <InterestOnSavRevAndExpnssAmt>167946</InterestOnSavRevAndExpnssAmt>
        <InterestOnSavNetInvstIncmAmt>158481</InterestOnSavNetInvstIncmAmt>
        <NetGainSaleAstRevAndExpnssAmt>0</NetGainSaleAstRevAndExpnssAmt>
        <GrossSalesPriceAmt>42388</GrossSalesPriceAmt>
        <CapGainNetIncmNetInvstIncmAmt>570</CapGainNetIncmNetInvstIncmAmt>
        <TotalRevAndExpnssAmt>305177946</TotalRevAndExpnssAmt>
        <TotalNetInvstIncmAmt>159051</TotalNetInvstIncmAmt>
        <CompOfcrDirTrstRevAndExpnssAmt>0</CompOfcrDirTrstRevAndExpnssAmt>
        <CompOfcrDirTrstNetInvstIncmAmt>0</CompOfcrDirTrstNetInvstIncmAmt>
        <CompOfcrDirTrstDsbrsChrtblAmt>0</CompOfcrDirTrstDsbrsChrtblAmt>
        <LegalFeesRevAndExpnssAmt referenceDocumentId="RetDoc2002100001">3720</LegalFeesRevAndExpnssAmt>
        <LegalFeesNetInvstIncmAmt>0</LegalFeesNetInvstIncmAmt>
        <LegalFeesDsbrsChrtblAmt>3690</LegalFeesDsbrsChrtblAmt>
        <AccountingFeesRevAndExpnssAmt referenceDocumentId="RetDoc2002200001">49019</AccountingFeesRevAndExpnssAmt>
        <AccountingFeesNetInvstIncmAmt>0</AccountingFeesNetInvstIncmAmt>
        <AccountingFeesChrtblPrpsAmt>13900</AccountingFeesChrtblPrpsAmt>
        <TravConfMeetingRevAndExpnssAmt>9976</TravConfMeetingRevAndExpnssAmt>
        <TravConfMeetingNetInvstIncmAmt>0</TravConfMeetingNetInvstIncmAmt>
        <TravConfMeetingDsbrsChrtblAmt>9976</TravConfMeetingDsbrsChrtblAmt>
        <OtherExpensesRevAndExpnssAmt referenceDocumentId="RetDoc2003200001">155486</OtherExpensesRevAndExpnssAmt>
        <OtherExpensesNetInvstIncmAmt>675</OtherExpensesNetInvstIncmAmt>
        <OtherExpensesDsbrsChrtblAmt>154811</OtherExpensesDsbrsChrtblAmt>
        <TotOprExpensesRevAndExpnssAmt>218201</TotOprExpensesRevAndExpnssAmt>
        <TotOprExpensesNetInvstIncmAmt>675</TotOprExpensesNetInvstIncmAmt>
        <TotOprExpensesDsbrsChrtblAmt>182377</TotOprExpensesDsbrsChrtblAmt>
        <ContriPaidRevAndExpnssAmt>11523315</ContriPaidRevAndExpnssAmt>
        <ContriPaidDsbrsChrtblAmt>6638495</ContriPaidDsbrsChrtblAmt>
        <TotalExpensesRevAndExpnssAmt>11741516</TotalExpensesRevAndExpnssAmt>
        <TotalExpensesNetInvstIncmAmt>675</TotalExpensesNetInvstIncmAmt>
        <TotalExpensesDsbrsChrtblAmt>6820872</TotalExpensesDsbrsChrtblAmt>
        <ExcessRevenueOverExpensesAmt>293436430</ExcessRevenueOverExpensesAmt>
        <NetInvestmentIncomeAmt>158376</NetInvestmentIncomeAmt>
      </AnalysisOfRevenueAndExpenses>
      <Form990PFBalanceSheetsGrp>
        <SavAndTempCashInvstBOYAmt>4954281</SavAndTempCashInvstBOYAmt>
        <SavAndTempCashInvstEOYAmt>302381605</SavAndTempCashInvstEOYAmt>
        <SavAndTempCashInvstEOYFMVAmt>302381605</SavAndTempCashInvstEOYFMVAmt>
        <CorporateBondsBOYAmt>0</CorporateBondsBOYAmt>
        <CorporateBondsEOYAmt referenceDocumentId="RetDoc2044400001">971288</CorporateBondsEOYAmt>
        <CorporateBondsEOYFMVAmt>971288</CorporateBondsEOYFMVAmt>
        <TotalAssetsBOYAmt>4954281</TotalAssetsBOYAmt>
        <TotalAssetsEOYAmt>303352893</TotalAssetsEOYAmt>
        <TotalAssetsEOYFMVAmt>303352893</TotalAssetsEOYFMVAmt>
        <AccountsPayableEOYAmt>35149</AccountsPayableEOYAmt>
        <GrantsPayableEOYAmt>9342375</GrantsPayableEOYAmt>
        <TotalLiabilitiesBOYAmt>0</TotalLiabilitiesBOYAmt>
        <TotalLiabilitiesEOYAmt>9377524</TotalLiabilitiesEOYAmt>
        <OrgDoesNotFollowFASB117Ind>X</OrgDoesNotFollowFASB117Ind>
        <CapitalStockBOYAmt>0</CapitalStockBOYAmt>
        <CapitalStockEOYAmt>0</CapitalStockEOYAmt>
        <AdditionalPaidInCapitalBOYAmt>0</AdditionalPaidInCapitalBOYAmt>
        <AdditionalPaidInCapitalEOYAmt>0</AdditionalPaidInCapitalEOYAmt>
        <RetainedEarningBOYAmt>4954281</RetainedEarningBOYAmt>
        <RetainedEarningEOYAmt>293975369</RetainedEarningEOYAmt>
        <TotNetAstOrFundBalancesBOYAmt>4954281</TotNetAstOrFundBalancesBOYAmt>
        <TotNetAstOrFundBalancesEOYAmt>293975369</TotNetAstOrFundBalancesEOYAmt>
        <TotalLiabilitiesNetAstBOYAmt>4954281</TotalLiabilitiesNetAstBOYAmt>
        <TotalLiabilitiesNetAstEOYAmt>303352893</TotalLiabilitiesNetAstEOYAmt>
      </Form990PFBalanceSheetsGrp>
      <ChgInNetAssetsFundBalancesGrp>
        <TotNetAstOrFundBalancesBOYAmt>4954281</TotNetAstOrFundBalancesBOYAmt>
        <ExcessRevenueOverExpensesAmt>293436430</ExcessRevenueOverExpensesAmt>
        <OtherIncreasesAmt referenceDocumentId="RetDoc2049700001">44426</OtherIncreasesAmt>
        <SubtotalAmt>298435137</SubtotalAmt>
        <OtherDecreasesAmt referenceDocumentId="RetDoc2049800001">4459768</OtherDecreasesAmt>
        <TotNetAstOrFundBalancesEOYAmt>293975369</TotNetAstOrFundBalancesEOYAmt>
      </ChgInNetAssetsFundBalancesGrp>
      <CapGainsLossTxInvstIncmDetail>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>18,000 SHARES OF ROYAL BK SCOTLND GRP PLC 6.0% 12/19/2023 USD SUB LIEN</PropertyDesc>
          <AcquiredDt>2022-05-23</AcquiredDt>
          <SoldDt>2022-08-10</SoldDt>
          <GrossSalesPriceAmt>18355</GrossSalesPriceAmt>
          <CostOrOtherBasisAmt>18496</CostOrOtherBasisAmt>
          <GainOrLossAmt>-141</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>-141</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>13,000 SHARES OF AMERICAN INTERNATIONAL GROUP, 3.9% 04/01/2026 USD SR LIEN</PropertyDesc>
          <AcquiredDt>2022-05-20</AcquiredDt>
          <SoldDt>2022-10-24</SoldDt>
          <GrossSalesPriceAmt>13033</GrossSalesPriceAmt>
          <CostOrOtherBasisAmt>12948</CostOrOtherBasisAmt>
          <GainOrLossAmt>85</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>85</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapGainsLossTxInvstIncmGrp>
          <PropertyDesc>11,000 SHARES OF VODAFONE GROUP PUBLIC LIMITED 4.375% 05/30/2028 USD SR LIEN</PropertyDesc>
          <AcquiredDt>2022-11-01</AcquiredDt>
          <SoldDt>2022-12-14</SoldDt>
          <GrossSalesPriceAmt>11000</GrossSalesPriceAmt>
          <CostOrOtherBasisAmt>10374</CostOrOtherBasisAmt>
          <GainOrLossAmt>626</GainOrLossAmt>
          <GainsMinusExcessOrLossesAmt>626</GainsMinusExcessOrLossesAmt>
        </CapGainsLossTxInvstIncmGrp>
        <CapitalGainNetIncomeAmt>570</CapitalGainNetIncomeAmt>
      </CapGainsLossTxInvstIncmDetail>
      <ExciseTaxBasedOnInvstIncmGrp>
        <InvestmentIncomeExciseTaxAmt>2201</InvestmentIncomeExciseTaxAmt>
        <TaxUnderSection511Amt>0</TaxUnderSection511Amt>
        <SubtotalAmt>2201</SubtotalAmt>
        <SubtitleATaxAmt>0</SubtitleATaxAmt>
        <TaxBasedOnInvestmentIncomeAmt>2201</TaxBasedOnInvestmentIncomeAmt>
        <EstimatedPlusOvpmtIncmTxAmt>0</EstimatedPlusOvpmtIncmTxAmt>
        <ExemptFrgnOrgTaxWthldAtSrceAmt>0</ExemptFrgnOrgTaxWthldAtSrceAmt>
        <ExtsnRequestIncomeTaxPaidAmt>0</ExtsnRequestIncomeTaxPaidAmt>
        <BackupWithholdingWithheldAmt>0</BackupWithholdingWithheldAmt>
        <TotalPaymentsAndCreditsAmt>0</TotalPaymentsAndCreditsAmt>
        <EsPenaltyAmt>103</EsPenaltyAmt>
        <TaxDueAmt>2304</TaxDueAmt>
      </ExciseTaxBasedOnInvstIncmGrp>
      <StatementsRegardingActyGrp>
        <LegislativePoliticalActyInd>0</LegislativePoliticalActyInd>
        <MoreThan100SpentInd>0</MoreThan100SpentInd>
        <Form1120POLFiledInd>0</Form1120POLFiledInd>
        <Section4955OrganizationTaxAmt>0</Section4955OrganizationTaxAmt>
        <Section4955ManagersTaxAmt>0</Section4955ManagersTaxAmt>
        <TaxReimbursedAmt>0</TaxReimbursedAmt>
        <ActivitiesNotPreviouslyRptInd>0</ActivitiesNotPreviouslyRptInd>
        <ChangesToArticlesOrBylawsInd>0</ChangesToArticlesOrBylawsInd>
        <UnrelatedBusIncmOverLimitInd>0</UnrelatedBusIncmOverLimitInd>
        <OrganizationDissolvedEtcInd>0</OrganizationDissolvedEtcInd>
        <Section508eRqrSatisfiedInd>1</Section508eRqrSatisfiedInd>
        <AtLeast5000InAssetsInd>1</AtLeast5000InAssetsInd>
        <OrgReportOrRegisterStateCd>CA</OrgReportOrRegisterStateCd>
        <Form990PFFiledWithAttyGenInd>1</Form990PFFiledWithAttyGenInd>
        <PrivateOperatingFoundationInd>0</PrivateOperatingFoundationInd>
        <NewSubstantialContributorsInd>0</NewSubstantialContributorsInd>
        <OwnControlledEntityInd>0</OwnControlledEntityInd>
        <DonorAdvisedFundInd>0</DonorAdvisedFundInd>
        <ComplyWithPublicInspRqrInd>1</ComplyWithPublicInspRqrInd>
        <WebsiteAddressTxt>N/A</WebsiteAddressTxt>
        <IndividualWithBooksNm>TORREY COAST FOUNDATION</IndividualWithBooksNm>
        <PhoneNum>8587548156</PhoneNum>
        <LocationOfBooksUSAddress>
          <AddressLine1Txt>5930 CORNERSTONE COURT WEST SUITE</AddressLine1Txt>
          <AddressLine2Txt>300</AddressLine2Txt>
          <CityNm>SAN DIEGO</CityNm>
          <StateAbbreviationCd>CA</StateAbbreviationCd>
          <ZIPCd>92121</ZIPCd>
        </LocationOfBooksUSAddress>
        <ForeignAccountsQuestionInd>0</ForeignAccountsQuestionInd>
      </StatementsRegardingActyGrp>
      <StatementsRegardingActy4720Grp>
        <SaleOrExchDisqualifiedPrsnInd>0</SaleOrExchDisqualifiedPrsnInd>
        <BrrwOrLendDisqualifiedPrsnInd>0</BrrwOrLendDisqualifiedPrsnInd>
        <FurnGoodsDisqualifiedPrsnInd>1</FurnGoodsDisqualifiedPrsnInd>
        <PayCompDisqualifiedPrsnInd>0</PayCompDisqualifiedPrsnInd>
        <TransferAstDisqualifiedPrsnInd>0</TransferAstDisqualifiedPrsnInd>
        <PaymentToGovernmentOfficialInd>0</PaymentToGovernmentOfficialInd>
        <ActsFailToQlfyAsExceptionsInd>0</ActsFailToQlfyAsExceptionsInd>
        <UncorrectedPriorActsInd>0</UncorrectedPriorActsInd>
        <UndistributedIncomePYInd>0</UndistributedIncomePYInd>
        <BusinessHoldingsInd>0</BusinessHoldingsInd>
        <JeopardyInvestmentsInd>0</JeopardyInvestmentsInd>
        <UncorrectedPYJeopardyInvstInd>0</UncorrectedPYJeopardyInvstInd>
        <InfluenceLegislationInd>0</InfluenceLegislationInd>
        <InfluenceElectionInd>0</InfluenceElectionInd>
        <GrantsToIndividualsInd>0</GrantsToIndividualsInd>
        <GrantsToOrganizationsInd>0</GrantsToOrganizationsInd>
        <NoncharitablePurposeInd>0</NoncharitablePurposeInd>
        <RcvFndsToPayPrsnlBnftCntrctInd>0</RcvFndsToPayPrsnlBnftCntrctInd>
        <PayPremiumsPrsnlBnftCntrctInd>0</PayPremiumsPrsnlBnftCntrctInd>
        <ProhibitedTaxShelterTransInd>0</ProhibitedTaxShelterTransInd>
        <SubjToTaxRmnrtnExPrchtPymtInd>0</SubjToTaxRmnrtnExPrchtPymtInd>
      </StatementsRegardingActy4720Grp>
      <OfficerDirTrstKeyEmplInfoGrp>
        <OfficerDirTrstKeyEmplGrp>
          <PersonNm>ALAN BRAYNIN</PersonNm>
          <USAddress>
            <AddressLine1Txt>2178 PINAR PLACE</AddressLine1Txt>
            <CityNm>DEL MAR</CityNm>
            <StateAbbreviationCd>CA</StateAbbreviationCd>
            <ZIPCd>92014</ZIPCd>
          </USAddress>
          <TitleTxt>PRESIDENT</TitleTxt>
          <AverageHrsPerWkDevotedToPosRt>15.00</AverageHrsPerWkDevotedToPosRt>
          <CompensationAmt>0</CompensationAmt>
          <EmployeeBenefitProgramAmt>0</EmployeeBenefitProgramAmt>
          <ExpenseAccountOtherAllwncAmt>0</ExpenseAccountOtherAllwncAmt>
        </OfficerDirTrstKeyEmplGrp>
        <CompOfHghstPdEmplOrNONETxt>NONE</CompOfHghstPdEmplOrNONETxt>
        <OtherEmployeePaidOver50kCnt>0</OtherEmployeePaidOver50kCnt>
        <CompOfHghstPdCntrctOrNONETxt>NONE</CompOfHghstPdCntrctOrNONETxt>
        <ContractorPaidOver50kCnt>0</ContractorPaidOver50kCnt>
      </OfficerDirTrstKeyEmplInfoGrp>
      <SumOfProgramRelatedInvstGrp>
        <TotalAmt>0</TotalAmt>
      </SumOfProgramRelatedInvstGrp>
      <MinimumInvestmentReturnGrp>
        <AverageMonthlyFMVOfSecAmt>569089</AverageMonthlyFMVOfSecAmt>
        <AverageMonthlyCashBalancesAmt>15852905</AverageMonthlyCashBalancesAmt>
        <FMVAllOtherNoncharitableAstAmt>0</FMVAllOtherNoncharitableAstAmt>
        <TotalFMVOfUnusedAssetsAmt>16421994</TotalFMVOfUnusedAssetsAmt>
        <ReductionClaimedAmt>0</ReductionClaimedAmt>
        <AcquisitionIndebtednessAmt>0</AcquisitionIndebtednessAmt>
        <AdjustedTotalFMVOfUnusedAstAmt>16421994</AdjustedTotalFMVOfUnusedAstAmt>
        <CashDeemedCharitableAmt>246330</CashDeemedCharitableAmt>
        <NetVlNoncharitableAssetsAmt>16175664</NetVlNoncharitableAssetsAmt>
        <MinimumInvestmentReturnAmt>808783</MinimumInvestmentReturnAmt>
      </MinimumInvestmentReturnGrp>
      <DistributableAmountGrp>
        <MinimumInvestmentReturnAmt>808783</MinimumInvestmentReturnAmt>
        <TaxBasedOnInvestmentIncomeAmt>2201</TaxBasedOnInvestmentIncomeAmt>
        <TotalTaxAmt>2201</TotalTaxAmt>
        <DistributableBeforeAdjAmt>806582</DistributableBeforeAdjAmt>
        <RecoveriesQualfiedDistriAmt>0</RecoveriesQualfiedDistriAmt>
        <DistributableBeforeDedAmt>806582</DistributableBeforeDedAmt>
        <DeductionFromDistributableAmt>0</DeductionFromDistributableAmt>
        <DistributableAsAdjustedAmt>806582</DistributableAsAdjustedAmt>
      </DistributableAmountGrp>
      <PFQualifyingDistributionsGrp>
        <ExpensesAndContributionsAmt>6820872</ExpensesAndContributionsAmt>
        <ProgramRelatedInvstTotalAmt>0</ProgramRelatedInvstTotalAmt>
        <QualifyingDistributionsAmt>6820872</QualifyingDistributionsAmt>
      </PFQualifyingDistributionsGrp>
      <UndistributedIncomeGrp>
        <DistributableAsAdjustedAmt>806582</DistributableAsAdjustedAmt>
        <UndistributedIncomePYAmt>0</UndistributedIncomePYAmt>
        <TotalForPriorYearsAmt>0</TotalForPriorYearsAmt>
        <ExcessDistributionCyovYr2Amt>2826723</ExcessDistributionCyovYr2Amt>
        <ExcessDistributionCyovYr1Amt>1142008</ExcessDistributionCyovYr1Amt>
        <TotalExcessDistributionCyovAmt>3968731</TotalExcessDistributionCyovAmt>
        <QualifyingDistributionsAmt>6820872</QualifyingDistributionsAmt>
        <AppliedToYear1Amt>0</AppliedToYear1Amt>
        <AppliedToPriorYearsAmt>0</AppliedToPriorYearsAmt>
        <TreatedAsDistriFromCorpusAmt>0</TreatedAsDistriFromCorpusAmt>
        <AppliedToCurrentYearAmt>806582</AppliedToCurrentYearAmt>
        <RemainingDistriFromCorpusAmt>6014290</RemainingDistriFromCorpusAmt>
        <ExcessDistriCyovAppCYCorpusAmt>0</ExcessDistriCyovAppCYCorpusAmt>
        <ExcessDistributionCyovAppCYAmt>0</ExcessDistributionCyovAppCYAmt>
        <TotalCorpusAmt>9983021</TotalCorpusAmt>
        <PriorYearUndistributedIncmAmt>0</PriorYearUndistributedIncmAmt>
        <PriorYearDeficiencyOrTaxAmt>0</PriorYearDeficiencyOrTaxAmt>
        <Taxable1Amt>0</Taxable1Amt>
        <Taxable2Amt>0</Taxable2Amt>
        <UndistributedIncomeCYAmt>0</UndistributedIncomeCYAmt>
        <CorpusDistri170b1EOr4942g3Amt>0</CorpusDistri170b1EOr4942g3Amt>
        <ExcessDistriCyovFromYr5Amt>0</ExcessDistriCyovFromYr5Amt>
        <ExcessDistriCyovToNextYrAmt>9983021</ExcessDistriCyovToNextYrAmt>
        <ExcessFromYear2Amt>2826723</ExcessFromYear2Amt>
        <ExcessFromYear1Amt>1142008</ExcessFromYear1Amt>
        <ExcessFromCurrentYearAmt>6014290</ExcessFromCurrentYearAmt>
      </UndistributedIncomeGrp>
      <SupplementaryInformationGrp>
        <ContributingManagerNm>ALAN BRAYNIN</ContributingManagerNm>
        <ApplicationSubmissionInfoGrp>
          <RecipientPersonNm>ALAN BRAYNIN</RecipientPersonNm>
          <RecipientUSAddress>
            <AddressLine1Txt>5390 CORNERSTONE COURT WEST SUITE</AddressLine1Txt>
            <AddressLine2Txt>300</AddressLine2Txt>
            <CityNm>SAN DIEGO</CityNm>
            <StateAbbreviationCd>CA</StateAbbreviationCd>
            <ZIPCd>92121</ZIPCd>
          </RecipientUSAddress>
          <RecipientPhoneNum>8587548156</RecipientPhoneNum>
          <RecipientEmailAddressTxt>HTTPS://WWW.TEAMGEMINI.ORG/GRANTS-AND-FUNDING</RecipientEmailAddressTxt>
          <FormAndInfoAndMaterialsTxt>APPLICATIONS ARE TO BE SUBMITTED ON THE TEAM GEMINI WEBSITE. SUBMISSIONS MUST INCLUDE A BIOSKETCH, A JUSTIFIED BUDGET, AND A TWO PAGE PROPOSAL THAT INCLUDES BACKGROUND, PROPOSED EXPERIMENTS, RATIONALE, EXPECTED OUTCOME, AND TIMELINE.</FormAndInfoAndMaterialsTxt>
          <SubmissionDeadlinesTxt>NO SUBMISSION DEADLINES.</SubmissionDeadlinesTxt>
          <RestrictionsOnAwardsTxt>RESTRICTED TO PRECLINICAL RESEARCH AND PHASE 1 TRIALS TREATING GASTROESOPHAGEAL CANCER.</RestrictionsOnAwardsTxt>
        </ApplicationSubmissionInfoGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CASE WESTERN RESERVE UNIVERSITY</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>10900 EUCLID AVENUE</AddressLine1Txt>
            <CityNm>CLEVELAND</CityNm>
            <StateAbbreviationCd>OH</StateAbbreviationCd>
            <ZIPCd>44106</ZIPCd>
          </RecipientUSAddress>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>COLLABORATION WITH THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER AND COLUMBIA UNIVERSITY'S GI ONCOLOGY TEAMS.</GrantOrContributionPurposeTxt>
          <Amt>46000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>COLUMBIA UNIVERSITY</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>630 WEST 168TH STREET</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10032</ZIPCd>
          </RecipientUSAddress>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>FOR CENTRALIZING GASTROESOPHAGEAL CANCER RESOURCES GIFT FUND, GRANT PROPOSAL" GENERATING GASTROESOPHAGEAL TUMOR TISSUE MICROARRAYTS", TO ESTABLISH THE TORREY COAST STRATEGIC RESEARCH FUND, WHICH SHALL BE USED TO SUPPORT GASTRIC AND ESOPHAGEAL CANCER RESEARCH, TO CONDUCT THE SCIENCE DESCRIBED IN DR. WANG AND BASS'S PROPOSAL,"TARGETING MYELOID CELLS TO ENHANCE IMMUNOTHERAPY TARGETING T CELLS", AND FOR GRANT PROPOSAL" GENERATING GASTROESOPHAGEAL TUMOR TISSUE MICROARRAYTS".</GrantOrContributionPurposeTxt>
          <Amt>1017800</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CORNELL UNIVERSITY - THE JOAN AND SANFORD I WEILL MEDICAL COLLEGE</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1300 YORK AVENUE</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10065</ZIPCd>
          </RecipientUSAddress>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>TO PROMOTE AND ENHANCE THE WORK OF THE MEDICAL COLLEGE THROUGH THE SUPPORT OF RESEARCH TO GENERATE INFORMATION ON THE MECHANISMS OF "DIFFUSE" MESENCHYMAL TYPE OF GASTRIC CANCER AND TO PROMOTE AND ENHANCE THE WORK OF THE MEDICAL COLLEGE THROUGH THE SUPPORT OF RESEARCH IN IDENTIFYING AND TESTING EVIDENCE-BASED TARGETED THERAPEUTIC STRATEGIES IN GASTRIC CANCER: TARGETING TGF AND THE IMMUNE MICROENVIRONMENT.</GrantOrContributionPurposeTxt>
          <Amt>574998</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>EMORY UNIVERSITY SCHOOL OF MEDICINE</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>201 DOWMAN DR</AddressLine1Txt>
            <CityNm>ATLANTA</CityNm>
            <StateAbbreviationCd>GA</StateAbbreviationCd>
            <ZIPCd>30322</ZIPCd>
          </RecipientUSAddress>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>FOR GRANT PROPOSAL" ADENOSQUAMOUS CARCINOMAS OF THE ESOPHAGUS: UNIQUE BIOLOGICAL AND THERAPEUTIC INSIGHTS FROM A RARE CANCER".</GrantOrContributionPurposeTxt>
          <Amt>76890</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>HIAS INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1300 SPRING ST STE 500</AddressLine1Txt>
            <CityNm>SILVER SPRING</CityNm>
            <StateAbbreviationCd>MD</StateAbbreviationCd>
            <ZIPCd>20910</ZIPCd>
          </RecipientUSAddress>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>TO SUPPORT UKRANIAN REFUGEES SEEKING SAFETY IN JEWISH COMMUNITIES IN EUROPE.</GrantOrContributionPurposeTxt>
          <Amt>100000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>INSITITUE OF MOLECULAR CELL BIOLOGY</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientForeignAddress>
            <AddressLine1Txt>8A BIOMEDICAL GROVE</AddressLine1Txt>
            <CityNm>IMMUNOS</CityNm>
            <CountryCd>SN</CountryCd>
            <ForeignPostalCd>138648</ForeignPostalCd>
          </RecipientForeignAddress>
          <RecipientFoundationStatusTxt>GOV</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>FOR GRANT PROPOSAL "EVALUATING GASTRIC CANCER THERAPEUTICS IN OUR CLDN18-ATK GENETICALLY ENGINEERED MOUSE MODEL OF GASTRIC CANCER".</GrantOrContributionPurposeTxt>
          <Amt>247000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>MASSACHUSETTES GENERAL HOSPITAL</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>55 FRUIT STREET</AddressLine1Txt>
            <CityNm>BOSTON</CityNm>
            <StateAbbreviationCd>MA</StateAbbreviationCd>
            <ZIPCd>02114</ZIPCd>
          </RecipientUSAddress>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>TO SUPPORT RSEARCH INCLUDING, BUT NOT LIMITED TO, EX-VIVO SENSITIVITY TESTING, BIOSENSOR EFFORTS, AND IDENTIFICATION OF DRUG AGENTS TO GENERATE CLINICAL TRIAL PILOT DATA IN REGARDS TO THE TREATMENTS OF ESOPHAGOGASTRIC CANCER</GrantOrContributionPurposeTxt>
          <Amt>101200</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>MEMORIAL SLOAN-KETTERING CANCER CENTER</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1275 YORK AVENUE</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10065</ZIPCd>
          </RecipientUSAddress>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>TO ORGANIZE RESEARCH IN ESOPHAGOGASTRIC CANCER UNDER THE DIRECTION OF DRS. YELENA JANJIGIAN AND KARUNA GANESH.</GrantOrContributionPurposeTxt>
          <Amt>396426</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE BROAD INSTITUTE INC</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>96 CALIFORNIA INSTITUTE OF</AddressLine1Txt>
            <AddressLine2Txt>TECHNOLOGY 360 S WILSON AVE</AddressLine2Txt>
            <CityNm>PASADENA</CityNm>
            <StateAbbreviationCd>CA</StateAbbreviationCd>
            <ZIPCd>91106</ZIPCd>
          </RecipientUSAddress>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>FOR THE PROJECT, ADAPTING 3D CANCER ORGANOIDS INTO MONOLAYER CELL LINES TO EXPAND MODEL UTILIZATION AND FOR SCREENING COMPOUNDS USING THE PRISM SCREENING PLATFORM.</GrantOrContributionPurposeTxt>
          <Amt>513181</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE DEGREGORIO FAMILY FOUNDATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>120 BROADWAY</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10271</ZIPCd>
          </RecipientUSAddress>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>TO SUPPORT THE COLLABORATIVE RSERACH GRANTS FUNDED FOR GASTRIC AND ESOPHAGEAL CANCER RESEARCH,</GrantOrContributionPurposeTxt>
          <Amt>375000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE ENTERTAINMENT INDUSTRY FOUNDATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>10880 WILSHIRE BLVD STE 1400</AddressLine1Txt>
            <CityNm>LOS ANGELES</CityNm>
            <StateAbbreviationCd>CA</StateAbbreviationCd>
            <ZIPCd>90024</ZIPCd>
          </RecipientUSAddress>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>DONATION TO SU2C/EIF TO FUND CERTAIN CANCER RESEARCH PROJECTS.</GrantOrContributionPurposeTxt>
          <Amt>1500000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UC SAN DIEGO FOUNDATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>9500 GILMAN DRIVE 0940</AddressLine1Txt>
            <CityNm>LA JOLLA</CityNm>
            <StateAbbreviationCd>CA</StateAbbreviationCd>
            <ZIPCd>920930940</ZIPCd>
          </RecipientUSAddress>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>INSTITUTE FOR NETWORK MEDICINE FOR A STUDY ENTITLED "RAPID TRANSLATION OF NOVEL IMMUNE CELL-TARGETED THERAPEUTICS IN ESOPHAGEAL AND GASTROESOPHAGEAL CANCERS", INSTITUTE FOR NETWORK MEDICINE FOR RESEARCH OF THE AREA OF GASTRIC CANCER, AND MOORES CANCER CENTER IMMUNOTHERAPY INNOVATION FUND.</GrantOrContributionPurposeTxt>
          <Amt>1285000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UNIVERSITY OF PENNSYLVANIA SCHOOL OF MEDICINE</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>3400 CIVIC CENTER BLVD</AddressLine1Txt>
            <CityNm>PHILADELPHIA</CityNm>
            <StateAbbreviationCd>PA</StateAbbreviationCd>
            <ZIPCd>19104</ZIPCd>
          </RecipientUSAddress>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>FOR GRANT PROPOSAL "SYSTEMATIC IDENTIFICATION AND PRIORITIZATION OF IMMUNOTHERAPY TARGETS FOR TREATMENT OF GASTROESOPHAGEAL MALIGNANCIES".</GrantOrContributionPurposeTxt>
          <Amt>55000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1515 HOLCOMBE BLVD</AddressLine1Txt>
            <CityNm>HOUSTON</CityNm>
            <StateAbbreviationCd>TX</StateAbbreviationCd>
            <ZIPCd>77030</ZIPCd>
          </RecipientUSAddress>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>"PERSONALIZED THERAPY FOR PATIENTS WITH ARID1A DEFICIT GASTRIC ADENOCARCINOMA (GAC)".</GrantOrContributionPurposeTxt>
          <Amt>200000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <GrantOrContributionPdDurYrGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UNIVERSITY OF UTAH</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>201 PRESIDENTS CIRCLE</AddressLine1Txt>
            <CityNm>SALT LAKE CITY</CityNm>
            <StateAbbreviationCd>UT</StateAbbreviationCd>
            <ZIPCd>84112</ZIPCd>
          </RecipientUSAddress>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>TO DEVELOP AND TEST NOVEL THERAPEUTICS FOR GASTRIC CANCER</GrantOrContributionPurposeTxt>
          <Amt>150000</Amt>
        </GrantOrContributionPdDurYrGrp>
        <TotalGrantOrContriPdDurYrAmt>6638495</TotalGrantOrContriPdDurYrAmt>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>BROAD INSTITUTE</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>96 CALIFORNIA INSTITUTE OF</AddressLine1Txt>
            <AddressLine2Txt>TECHNOLOGY 360 S WILSON AVE</AddressLine2Txt>
            <CityNm>PASADENA</CityNm>
            <StateAbbreviationCd>CA</StateAbbreviationCd>
            <ZIPCd>91106</ZIPCd>
          </RecipientUSAddress>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>FOR THE PROJECT, ADAPTING 3D CANCER ORGANOIDS INTO MONOLAYER CELL LINES TO EXPAND MODEL UTILIZATION.</GrantOrContributionPurposeTxt>
          <Amt>127644</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>COLUMBIA UNIVERSITY</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>630 WEST 168TH STREET</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10032</ZIPCd>
          </RecipientUSAddress>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>TO ESTABLISH THE TORREY COAST STRATEGIC RESEARCH FUND. THE RESEARCH FUND SHALL BE USED TO SUPPORT GASTRIC AND ESOPHAGEAL CANCER RESEARCH.</GrantOrContributionPurposeTxt>
          <Amt>2000000</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>COLUMBIA UNIVERSITY</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>630 WEST 168TH STREET</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10032</ZIPCd>
          </RecipientUSAddress>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>"CENTRALIZING GASTROESOPHAGEAL CANCER RESOURCES GIFT FUND".</GrantOrContributionPurposeTxt>
          <Amt>150000</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CORNELL UNIVERSITY - THE JOAN AND SANFORD I WEILL MEDICAL COLLEGE</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1300 YORK AVENUE</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10065</ZIPCd>
          </RecipientUSAddress>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>TO PROMOTE AND ENHANCE THE WORK OF THE MEDICAL COLLEGE THROUGH THE SUPPORT OF RESEARCH IN IDENTIFYING AND TESTING EVIDENCE-BASED TARGETED THERAPEUTIC STRATEGIES IN GASTRIC CANCER: TARGETING TGF AND THE IMMUNE MICROENVIRONMENT.</GrantOrContributionPurposeTxt>
          <Amt>62400</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>CORNELL UNIVERSITY - THE JOAN AND SANFORD I WEILL MEDICAL COLLEGE</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>1300 YORK AVENUE</AddressLine1Txt>
            <CityNm>NEW YORK</CityNm>
            <StateAbbreviationCd>NY</StateAbbreviationCd>
            <ZIPCd>10065</ZIPCd>
          </RecipientUSAddress>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>TO PROMOTE AND ENHANCE THE WORK OF THE MEDICAL COLLEGE THROUGH THE SUPPORT OF RESEARCH TITLED "ABROGATION OF NEUTROPHIL MEDIATED PRO-TUMORIGENIC INTERACTIONS WITH ESOPHAGEAL AND GASTRIC ADENOCARCINOMAS."</GrantOrContributionPurposeTxt>
          <Amt>200000</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>THE ENTERTAINMENT INDUSTRY FOUNDATION</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>10880 WILSHIRE BLVD STE 1400</AddressLine1Txt>
            <CityNm>LOS ANGELES</CityNm>
            <StateAbbreviationCd>CA</StateAbbreviationCd>
            <ZIPCd>90024</ZIPCd>
          </RecipientUSAddress>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>DONATION TO SU2C/EIF TO FUND CERTAIN CANCER RESEARCH PROJECTS.</GrantOrContributionPurposeTxt>
          <Amt>4500000</Amt>
        </GrantOrContriApprvForFutGrp>
        <GrantOrContriApprvForFutGrp>
          <RecipientBusinessName>
            <BusinessNameLine1Txt>UNIVERSITY OF PENNSYLVANIA SCHOOL OF MEDICINE</BusinessNameLine1Txt>
          </RecipientBusinessName>
          <RecipientUSAddress>
            <AddressLine1Txt>3400 CIVIC CENTER BLVD</AddressLine1Txt>
            <CityNm>PHILADELPHIA</CityNm>
            <StateAbbreviationCd>PA</StateAbbreviationCd>
            <ZIPCd>19104</ZIPCd>
          </RecipientUSAddress>
          <RecipientFoundationStatusTxt>PC</RecipientFoundationStatusTxt>
          <GrantOrContributionPurposeTxt>FOR GRANT PROPOSAL "SYSTEMATIC IDENTIFICATION AND PRIORITIZATION OF IMMUNOTHERAPY TARGETS FOR TREATMENT OF GASTROESOPHAGEAL MALIGNANCIES."</GrantOrContributionPurposeTxt>
          <Amt>55000</Amt>
        </GrantOrContriApprvForFutGrp>
        <TotalGrantOrContriApprvFutAmt>7095044</TotalGrantOrContriApprvFutAmt>
      </SupplementaryInformationGrp>
      <AnalysisIncomeProducingActyGrp>
        <IntOnSavAndTempCashInvstGrp>
          <ExclusionCd>14</ExclusionCd>
          <ExclusionAmt>167946</ExclusionAmt>
        </IntOnSavAndTempCashInvstGrp>
        <GainSalesAstOthThanInvntryGrp>
          <ExclusionCd>18</ExclusionCd>
        </GainSalesAstOthThanInvntryGrp>
        <SubtotalsIncmProducingActyGrp>
          <UnrelatedBusinessTaxblIncmAmt>0</UnrelatedBusinessTaxblIncmAmt>
          <ExclusionAmt>167946</ExclusionAmt>
          <RelatedOrExemptFunctionIncmAmt>0</RelatedOrExemptFunctionIncmAmt>
        </SubtotalsIncmProducingActyGrp>
        <TotalIncomeProducingActyAmt>167946</TotalIncomeProducingActyAmt>
      </AnalysisIncomeProducingActyGrp>
      <RlnOfActyToAccomOfExmptPrpsGrp>
        <RlnOfActyToAccomOfExmptPrpsGrp>
          <LineNumberTxt>1</LineNumberTxt>
          <RelationshipStatementTxt>N/A</RelationshipStatementTxt>
        </RlnOfActyToAccomOfExmptPrpsGrp>
      </RlnOfActyToAccomOfExmptPrpsGrp>
      <TrnsfrTransRlnNonchrtblEOGrp>
        <TrnsfrOfCashToNonchrtblEOInd>0</TrnsfrOfCashToNonchrtblEOInd>
        <TrnsfrOtherAssetNonchrtblEOInd>0</TrnsfrOtherAssetNonchrtblEOInd>
        <SalesOrExchangesOfAssetsInd>0</SalesOrExchangesOfAssetsInd>
        <PurchaseOfAssetsNonchrtblEOInd>0</PurchaseOfAssetsNonchrtblEOInd>
        <RentalOfFacilitiesOthAssetsInd>0</RentalOfFacilitiesOthAssetsInd>
        <ReimbursementArrangementsInd>0</ReimbursementArrangementsInd>
        <LoansOrLoanGuaranteesInd>0</LoansOrLoanGuaranteesInd>
        <PerformanceOfServicesEtcInd>0</PerformanceOfServicesEtcInd>
        <SharingOfFacilitiesEtcInd>0</SharingOfFacilitiesEtcInd>
        <RelationshipsNonchrtblEOInd>0</RelationshipsNonchrtblEOInd>
      </TrnsfrTransRlnNonchrtblEOGrp>
    </IRS990PF>
    <IRS990ScheduleB documentId="RetDoc1234500001">
      <Organization501c3ExemptPFInd>X</Organization501c3ExemptPFInd>
      <GeneralRuleInd>X</GeneralRuleInd>
      <ContributorInformationGrp>
        <ContributorNum>1</ContributorNum>
        <ContributorPersonNm>ALAN BRAYNIN</ContributorPersonNm>
        <ContributorUSAddress>
          <AddressLine1Txt>2178 PINAR PLACE</AddressLine1Txt>
          <CityNm>DEL MAR</CityNm>
          <StateAbbreviationCd>CA</StateAbbreviationCd>
          <ZIPCd>92014</ZIPCd>
        </ContributorUSAddress>
        <TotalContributionsAmt>305010000</TotalContributionsAmt>
        <PersonContributionInd>X</PersonContributionInd>
      </ContributorInformationGrp>
    </IRS990ScheduleB>
    <AccountingFeesSchedule documentId="RetDoc2002200001">
      <AccountingFeesDetail>
        <CategoryTxt>TAX PREPARATION FEES</CategoryTxt>
        <Amt>49019</Amt>
        <NetInvestmentIncomeAmt>0</NetInvestmentIncomeAmt>
        <DisbursementsCharitablePrpsAmt>13900</DisbursementsCharitablePrpsAmt>
      </AccountingFeesDetail>
    </AccountingFeesSchedule>
    <InvestmentsCorpBondsSchedule documentId="RetDoc2044400001">
      <InvestmentsCorporateBondsGrp>
        <BondNm>EBAY INC. 2.75% 01/30/2023 SR LIEN S&amp;P BBB+ /MOODY'S</BondNm>
        <EOYBookValueAmt>22216</EOYBookValueAmt>
        <EOYFMVAmt>22216</EOYFMVAmt>
      </InvestmentsCorporateBondsGrp>
      <InvestmentsCorporateBondsGrp>
        <BondNm>NEXTERA ENERGY CAPITAL 0.65% 03/01/2023 SR LIEN S&amp;P</BondNm>
        <EOYBookValueAmt>6967</EOYBookValueAmt>
        <EOYFMVAmt>6967</EOYFMVAmt>
      </InvestmentsCorporateBondsGrp>
      <InvestmentsCorporateBondsGrp>
        <BondNm>ENERGY TRANSFER OPERATNG 4.25% 03/15/2023 SER * SR</BondNm>
        <EOYBookValueAmt>8081</EOYBookValueAmt>
        <EOYFMVAmt>8081</EOYFMVAmt>
      </InvestmentsCorporateBondsGrp>
      <InvestmentsCorporateBondsGrp>
        <BondNm>ILLUMINA, INC 0.55% 03/23/2023 SR LIEN S&amp;P BBB /MOODY'S</BondNm>
        <EOYBookValueAmt>19825</EOYBookValueAmt>
        <EOYFMVAmt>19825</EOYFMVAmt>
      </InvestmentsCorporateBondsGrp>
      <InvestmentsCorporateBondsGrp>
        <BondNm>MCDONALD'S CORPORATION MTN 3.35% 04/01/2023 SR LIEN</BondNm>
        <EOYBookValueAmt>17078</EOYBookValueAmt>
        <EOYFMVAmt>17078</EOYFMVAmt>
      </InvestmentsCorporateBondsGrp>
      <InvestmentsCorporateBondsGrp>
        <BondNm>UNITED PARCEL SERVICE, INC. 2.5% 04/01/2023 SR LIEN NEXT</BondNm>
        <EOYBookValueAmt>7001</EOYBookValueAmt>
        <EOYFMVAmt>7001</EOYFMVAmt>
      </InvestmentsCorporateBondsGrp>
      <InvestmentsCorporateBondsGrp>
        <BondNm>DELMARVA POWER &amp; LIGHT COMPANY 3.5% 11/15/2023 USD</BondNm>
        <EOYBookValueAmt>16850</EOYBookValueAmt>
        <EOYFMVAmt>16850</EOYFMVAmt>
      </InvestmentsCorporateBondsGrp>
      <InvestmentsCorporateBondsGrp>
        <BondNm>MORGAN STANLEY HYBRID MTN 01/25/2024 USD SR LIEN</BondNm>
        <EOYBookValueAmt>24890</EOYBookValueAmt>
        <EOYFMVAmt>24890</EOYFMVAmt>
      </InvestmentsCorporateBondsGrp>
      <InvestmentsCorporateBondsGrp>
        <BondNm>BANK OF AMERICA CORPORATION HYBRID MTN 03/05/2024</BondNm>
        <EOYBookValueAmt>24189</EOYBookValueAmt>
        <EOYFMVAmt>24189</EOYFMVAmt>
      </InvestmentsCorporateBondsGrp>
      <InvestmentsCorporateBondsGrp>
        <BondNm>JPMORGAN CHASE &amp; CO. HYBRID 03/16/2024 USD SR LIEN</BondNm>
        <EOYBookValueAmt>24789</EOYBookValueAmt>
        <EOYFMVAmt>24789</EOYFMVAmt>
      </InvestmentsCorporateBondsGrp>
      <InvestmentsCorporateBondsGrp>
        <BondNm>CANADIAN IMPERIAL BANK OF COMM 1.0% 10/18/2024 USD</BondNm>
        <EOYBookValueAmt>24313</EOYBookValueAmt>
        <EOYFMVAmt>24313</EOYFMVAmt>
      </InvestmentsCorporateBondsGrp>
      <InvestmentsCorporateBondsGrp>
        <BondNm>EASTMAN CHEMICAL COMPANY 3.8% 03/15/2025 USD SR</BondNm>
        <EOYBookValueAmt>10804</EOYBookValueAmt>
        <EOYFMVAmt>10804</EOYFMVAmt>
      </InvestmentsCorporateBondsGrp>
      <InvestmentsCorporateBondsGrp>
        <BondNm>ALLY FINANCIAL INC. 4.625% 03/30/2025 USD SR LIEN S&amp;P</BondNm>
        <EOYBookValueAmt>8908</EOYBookValueAmt>
        <EOYFMVAmt>8908</EOYFMVAmt>
      </InvestmentsCorporateBondsGrp>
      <InvestmentsCorporateBondsGrp>
        <BondNm>MARATHON PETROLEUM CORP 4.7% 05/01/2025 USD SR LIEN</BondNm>
        <EOYBookValueAmt>18872</EOYBookValueAmt>
        <EOYFMVAmt>18872</EOYFMVAmt>
      </InvestmentsCorporateBondsGrp>
      <InvestmentsCorporateBondsGrp>
        <BondNm>INTERCONTINENTAL EXCHANGE, INC 3.65% 05/23/2025 USD</BondNm>
        <EOYBookValueAmt>13729</EOYBookValueAmt>
        <EOYFMVAmt>13729</EOYFMVAmt>
      </InvestmentsCorporateBondsGrp>
      <InvestmentsCorporateBondsGrp>
        <BondNm>VODAFONE GROUP PUBLIC LIMITED 4.125% 05/30/2025 USD</BondNm>
        <EOYBookValueAmt>3953</EOYBookValueAmt>
        <EOYFMVAmt>3953</EOYFMVAmt>
      </InvestmentsCorporateBondsGrp>
      <InvestmentsCorporateBondsGrp>
        <BondNm>KINDER MORGAN, INC. 4.3% 06/01/2025 USD SR LIEN NEXT</BondNm>
        <EOYBookValueAmt>17731</EOYBookValueAmt>
        <EOYFMVAmt>17731</EOYFMVAmt>
      </InvestmentsCorporateBondsGrp>
      <InvestmentsCorporateBondsGrp>
        <BondNm>NETAPP, INC. 1.875% 06/22/2025 USD SR LIEN NEXT CALL DT. 05</BondNm>
        <EOYBookValueAmt>18394</EOYBookValueAmt>
        <EOYFMVAmt>18394</EOYFMVAmt>
      </InvestmentsCorporateBondsGrp>
      <InvestmentsCorporateBondsGrp>
        <BondNm>BIOGEN INC. 4.05% 09/15/2025 USD SR LIEN NEXT CALL DT. 06</BondNm>
        <EOYBookValueAmt>18712</EOYBookValueAmt>
        <EOYFMVAmt>18712</EOYFMVAmt>
      </InvestmentsCorporateBondsGrp>
      <InvestmentsCorporateBondsGrp>
        <BondNm>ENBRIDGE ENERGY PARTNERS 5.875% 10/15/2025 USD SR</BondNm>
        <EOYBookValueAmt>5144</EOYBookValueAmt>
        <EOYFMVAmt>5144</EOYFMVAmt>
      </InvestmentsCorporateBondsGrp>
      <InvestmentsCorporateBondsGrp>
        <BondNm>THE BANK OF NOVA SCOTIA 4.5% 12/16/2025 USD SUB LIEN</BondNm>
        <EOYBookValueAmt>10811</EOYBookValueAmt>
        <EOYFMVAmt>10811</EOYFMVAmt>
      </InvestmentsCorporateBondsGrp>
      <InvestmentsCorporateBondsGrp>
        <BondNm>CBS CORPORATION 4.0% 01/15/2026 USD SR LIEN NEXT CALL</BondNm>
        <EOYBookValueAmt>18570</EOYBookValueAmt>
        <EOYFMVAmt>18570</EOYFMVAmt>
      </InvestmentsCorporateBondsGrp>
      <InvestmentsCorporateBondsGrp>
        <BondNm>SIMON PROPERTY GROUP, L.P. 3.3% 01/15/2026 USD SR LIEN</BondNm>
        <EOYBookValueAmt>16413</EOYBookValueAmt>
        <EOYFMVAmt>16413</EOYFMVAmt>
      </InvestmentsCorporateBondsGrp>
      <InvestmentsCorporateBondsGrp>
        <BondNm>ZIMMER BIOMET HOLDINGS 3.05% 01/15/2026 USD SR LIEN</BondNm>
        <EOYBookValueAmt>16288</EOYBookValueAmt>
        <EOYFMVAmt>16288</EOYFMVAmt>
      </InvestmentsCorporateBondsGrp>
      <InvestmentsCorporateBondsGrp>
        <BondNm>ROYAL BANK OF CANADA MTN 4.65% 01/27/2026 USD SUB</BondNm>
        <EOYBookValueAmt>23174</EOYBookValueAmt>
        <EOYFMVAmt>23174</EOYFMVAmt>
      </InvestmentsCorporateBondsGrp>
      <InvestmentsCorporateBondsGrp>
        <BondNm>BOEING COMPANY (THE) 2.196% 02/04/2026 USD SR LIEN</BondNm>
        <EOYBookValueAmt>14696</EOYBookValueAmt>
        <EOYFMVAmt>14696</EOYFMVAmt>
      </InvestmentsCorporateBondsGrp>
      <InvestmentsCorporateBondsGrp>
        <BondNm>ALTRIA GROUP, INC. 4.4% 02/14/2026 USD SR LIEN NEXT CALL</BondNm>
        <EOYBookValueAmt>4983</EOYBookValueAmt>
        <EOYFMVAmt>4983</EOYFMVAmt>
      </InvestmentsCorporateBondsGrp>
      <InvestmentsCorporateBondsGrp>
        <BondNm>SUMITOMO MITSUI FINANCIAL GROU 3.784% 03/09/2026</BondNm>
        <EOYBookValueAmt>21452</EOYBookValueAmt>
        <EOYFMVAmt>21452</EOYFMVAmt>
      </InvestmentsCorporateBondsGrp>
      <InvestmentsCorporateBondsGrp>
        <BondNm>AMERICAN INTERNATIONAL GROUP, 3.9% 04/01/2026 USD SR</BondNm>
        <EOYBookValueAmt>8815</EOYBookValueAmt>
        <EOYFMVAmt>8815</EOYFMVAmt>
      </InvestmentsCorporateBondsGrp>
      <InvestmentsCorporateBondsGrp>
        <BondNm>WELLS FARGO &amp; COMPANY HYBRID MTN 04/25/2026 USD SR</BondNm>
        <EOYBookValueAmt>23416</EOYBookValueAmt>
        <EOYFMVAmt>23416</EOYFMVAmt>
      </InvestmentsCorporateBondsGrp>
      <InvestmentsCorporateBondsGrp>
        <BondNm>SRS CCD 26745899 MTN 3.75% 06/01/2026 USD SR LIEN NEXT</BondNm>
        <EOYBookValueAmt>18809</EOYBookValueAmt>
        <EOYFMVAmt>18809</EOYFMVAmt>
      </InvestmentsCorporateBondsGrp>
      <InvestmentsCorporateBondsGrp>
        <BondNm>FISERV INC 3.2% 07/01/2026 USD SR LIEN NEXT CALL DT. 05 01</BondNm>
        <EOYBookValueAmt>19059</EOYBookValueAmt>
        <EOYFMVAmt>19059</EOYFMVAmt>
      </InvestmentsCorporateBondsGrp>
      <InvestmentsCorporateBondsGrp>
        <BondNm>THE SOUTHERN COMPANY 3.25% 07/01/2026 USD SR LIEN</BondNm>
        <EOYBookValueAmt>23941</EOYBookValueAmt>
        <EOYFMVAmt>23941</EOYFMVAmt>
      </InvestmentsCorporateBondsGrp>
      <InvestmentsCorporateBondsGrp>
        <BondNm>SYNCHRONY FINANCIAL 3.7% 08/04/2026 USD SR LIEN NEXT</BondNm>
        <EOYBookValueAmt>14042</EOYBookValueAmt>
        <EOYFMVAmt>14042</EOYFMVAmt>
      </InvestmentsCorporateBondsGrp>
      <InvestmentsCorporateBondsGrp>
        <BondNm>DELL INT LLC / EMC CORP 4.9% 10/01/2026 USD SR LIEN NEXT</BondNm>
        <EOYBookValueAmt>15967</EOYBookValueAmt>
        <EOYFMVAmt>15967</EOYFMVAmt>
      </InvestmentsCorporateBondsGrp>
      <InvestmentsCorporateBondsGrp>
        <BondNm>GENERAL MOTORS FINANCIAL COMPA 4.35% 01/17/2027 USD</BondNm>
        <EOYBookValueAmt>13593</EOYBookValueAmt>
        <EOYFMVAmt>13593</EOYFMVAmt>
      </InvestmentsCorporateBondsGrp>
      <InvestmentsCorporateBondsGrp>
        <BondNm>TRUIST FINANCIAL CORPORATION HYBRID MTN 03/02/2027</BondNm>
        <EOYBookValueAmt>21378</EOYBookValueAmt>
        <EOYFMVAmt>21378</EOYFMVAmt>
      </InvestmentsCorporateBondsGrp>
      <InvestmentsCorporateBondsGrp>
        <BondNm>B.A.T. CAPITAL CORPORATION 4.7% 04/02/2027 USD SR LIEN</BondNm>
        <EOYBookValueAmt>18459</EOYBookValueAmt>
        <EOYFMVAmt>18459</EOYFMVAmt>
      </InvestmentsCorporateBondsGrp>
      <InvestmentsCorporateBondsGrp>
        <BondNm>NXP B.V. 4.4% 06/01/2027 USD SR LIEN NXP FUNDING LLC /</BondNm>
        <EOYBookValueAmt>18287</EOYBookValueAmt>
        <EOYFMVAmt>18287</EOYFMVAmt>
      </InvestmentsCorporateBondsGrp>
      <InvestmentsCorporateBondsGrp>
        <BondNm>CITIGROUP INC. HYBRID 06/09/2027 USD SR LIEN CPN</BondNm>
        <EOYBookValueAmt>20864</EOYBookValueAmt>
        <EOYFMVAmt>20864</EOYFMVAmt>
      </InvestmentsCorporateBondsGrp>
      <InvestmentsCorporateBondsGrp>
        <BondNm>DIGITAL REALTY TRUST LP 3.7% 08/15/2027 USD SR LIEN NEXT</BondNm>
        <EOYBookValueAmt>18874</EOYBookValueAmt>
        <EOYFMVAmt>18874</EOYFMVAmt>
      </InvestmentsCorporateBondsGrp>
      <InvestmentsCorporateBondsGrp>
        <BondNm>ORACLE CORPORATION 3.25% 11/15/2027 USD SR LIEN NEXT</BondNm>
        <EOYBookValueAmt>13861</EOYBookValueAmt>
        <EOYFMVAmt>13861</EOYFMVAmt>
      </InvestmentsCorporateBondsGrp>
      <InvestmentsCorporateBondsGrp>
        <BondNm>STATE STREET CORPORATION HYBRID 11/18/2027 USD SR</BondNm>
        <EOYBookValueAmt>24003</EOYBookValueAmt>
        <EOYFMVAmt>24003</EOYFMVAmt>
      </InvestmentsCorporateBondsGrp>
      <InvestmentsCorporateBondsGrp>
        <BondNm>MPLX LP 4.25% 12/01/2027 USD SER WI SR LIEN NEXT CALL DT.</BondNm>
        <EOYBookValueAmt>18050</EOYBookValueAmt>
        <EOYFMVAmt>18050</EOYFMVAmt>
      </InvestmentsCorporateBondsGrp>
      <InvestmentsCorporateBondsGrp>
        <BondNm>AMERICAN TOWER CORPORATION 3.6% 01/15/2028 USD SR</BondNm>
        <EOYBookValueAmt>14057</EOYBookValueAmt>
        <EOYFMVAmt>14057</EOYFMVAmt>
      </InvestmentsCorporateBondsGrp>
      <InvestmentsCorporateBondsGrp>
        <BondNm>MITSUBISHI UFJ FINANCIAL GROUP 3.961% 03/02/2028 USD</BondNm>
        <EOYBookValueAmt>21223</EOYBookValueAmt>
        <EOYFMVAmt>21223</EOYFMVAmt>
      </InvestmentsCorporateBondsGrp>
      <InvestmentsCorporateBondsGrp>
        <BondNm>CVS HEALTH CORPORATION 4.3% 03/25/2028 USD SR LIEN</BondNm>
        <EOYBookValueAmt>18627</EOYBookValueAmt>
        <EOYFMVAmt>18627</EOYFMVAmt>
      </InvestmentsCorporateBondsGrp>
      <InvestmentsCorporateBondsGrp>
        <BondNm>AXA EQUITABLE HOLDINGS, INC. 4.35% 04/20/2028 USD SER</BondNm>
        <EOYBookValueAmt>4814</EOYBookValueAmt>
        <EOYFMVAmt>4814</EOYFMVAmt>
      </InvestmentsCorporateBondsGrp>
      <InvestmentsCorporateBondsGrp>
        <BondNm>CAPITAL ONE FINANCIAL CORPORA HYBRID 05/10/2028 USD</BondNm>
        <EOYBookValueAmt>21459</EOYBookValueAmt>
        <EOYFMVAmt>21459</EOYFMVAmt>
      </InvestmentsCorporateBondsGrp>
      <InvestmentsCorporateBondsGrp>
        <BondNm>KELLOGG CO 4.3% 05/15/2028 USD SR LIEN NEXT CALL DT. 02 15</BondNm>
        <EOYBookValueAmt>18548</EOYBookValueAmt>
        <EOYFMVAmt>18548</EOYFMVAmt>
      </InvestmentsCorporateBondsGrp>
      <InvestmentsCorporateBondsGrp>
        <BondNm>VERIZON COMMUNICATIONS, INC. 4.329% 09/21/2028 USD</BondNm>
        <EOYBookValueAmt>16580</EOYBookValueAmt>
        <EOYFMVAmt>16580</EOYFMVAmt>
      </InvestmentsCorporateBondsGrp>
      <InvestmentsCorporateBondsGrp>
        <BondNm>BANK OF MONTREAL HYBRID 10/05/2028 USD SUB LIEN CPN</BondNm>
        <EOYBookValueAmt>23771</EOYBookValueAmt>
        <EOYFMVAmt>23771</EOYFMVAmt>
      </InvestmentsCorporateBondsGrp>
      <InvestmentsCorporateBondsGrp>
        <BondNm>FOX CORPORATION 4.709% 01/25/2029 USD SER WI SR LIEN</BondNm>
        <EOYBookValueAmt>18788</EOYBookValueAmt>
        <EOYFMVAmt>18788</EOYFMVAmt>
      </InvestmentsCorporateBondsGrp>
      <InvestmentsCorporateBondsGrp>
        <BondNm>AMGEN INC. 3.0% 02/22/2029 USD SR LIEN NEXT CALL DT. 12</BondNm>
        <EOYBookValueAmt>7184</EOYBookValueAmt>
        <EOYFMVAmt>7184</EOYFMVAmt>
      </InvestmentsCorporateBondsGrp>
      <InvestmentsCorporateBondsGrp>
        <BondNm>NEXTERA ENERGY CAPITAL HOLDING 3.5% 04/01/2029 USD</BondNm>
        <EOYBookValueAmt>10111</EOYBookValueAmt>
        <EOYFMVAmt>10111</EOYFMVAmt>
      </InvestmentsCorporateBondsGrp>
      <InvestmentsCorporateBondsGrp>
        <BondNm>BROADCOM INC. 4.75% 04/15/2029 USD SER WI SR LIEN NEXT</BondNm>
        <EOYBookValueAmt>13503</EOYBookValueAmt>
        <EOYFMVAmt>13503</EOYFMVAmt>
      </InvestmentsCorporateBondsGrp>
      <InvestmentsCorporateBondsGrp>
        <BondNm>KEURIG DR PEPPER INC. 3.95% 04/15/2029 USD SR LIEN NEXT</BondNm>
        <EOYBookValueAmt>15991</EOYBookValueAmt>
        <EOYFMVAmt>15991</EOYFMVAmt>
      </InvestmentsCorporateBondsGrp>
      <InvestmentsCorporateBondsGrp>
        <BondNm>PRINCIPAL FINANCIAL GROUP, INC 3.7% 05/15/2029 USD SR</BondNm>
        <EOYBookValueAmt>4670</EOYBookValueAmt>
        <EOYFMVAmt>4670</EOYFMVAmt>
      </InvestmentsCorporateBondsGrp>
      <InvestmentsCorporateBondsGrp>
        <BondNm>U.S. BANCORP MTN 3.0% 07/30/2029 USD SUB LIEN NEXT CALL</BondNm>
        <EOYBookValueAmt>15178</EOYBookValueAmt>
        <EOYFMVAmt>15178</EOYFMVAmt>
      </InvestmentsCorporateBondsGrp>
      <InvestmentsCorporateBondsGrp>
        <BondNm>KEYCORP MTN 2.55% 10/01/2029 USD SR LIEN S&amp;P BBB+</BondNm>
        <EOYBookValueAmt>5949</EOYBookValueAmt>
        <EOYFMVAmt>5949</EOYFMVAmt>
      </InvestmentsCorporateBondsGrp>
      <InvestmentsCorporateBondsGrp>
        <BondNm>SKYWORKS SOLUTIONS, INC. 1.8% 06/01/2026 USD SR LIEN</BondNm>
        <EOYBookValueAmt>10584</EOYBookValueAmt>
        <EOYFMVAmt>10584</EOYFMVAmt>
      </InvestmentsCorporateBondsGrp>
    </InvestmentsCorpBondsSchedule>
    <LegalFeesSchedule documentId="RetDoc2002100001">
      <LegalFeesGrp>
        <CategoryTxt>LEGAL FEES</CategoryTxt>
        <LegalFeesAmt>3720</LegalFeesAmt>
        <NetInvestmentIncomeAmt>0</NetInvestmentIncomeAmt>
        <DisbursementsCharitablePrpsAmt>3690</DisbursementsCharitablePrpsAmt>
      </LegalFeesGrp>
    </LegalFeesSchedule>
    <OtherDecreasesSchedule documentId="RetDoc2049800001">
      <OtherDecreasesDetail>
        <Desc>PRIOR PERIOD ADJUSTMENT</Desc>
        <Amt>4459768</Amt>
      </OtherDecreasesDetail>
    </OtherDecreasesSchedule>
    <OtherExpensesSchedule documentId="RetDoc2003200001">
      <OtherExpensesScheduleGrp>
        <Desc>OFFICE EXPENSES</Desc>
        <RevenueAndExpensesPerBooksAmt>400</RevenueAndExpensesPerBooksAmt>
        <NetInvestmentIncomeAmt>0</NetInvestmentIncomeAmt>
        <DisbursementsCharitablePrpsAmt>400</DisbursementsCharitablePrpsAmt>
      </OtherExpensesScheduleGrp>
      <OtherExpensesScheduleGrp>
        <Desc>SHIPPING AND POSTAGE</Desc>
        <RevenueAndExpensesPerBooksAmt>16</RevenueAndExpensesPerBooksAmt>
        <NetInvestmentIncomeAmt>0</NetInvestmentIncomeAmt>
        <DisbursementsCharitablePrpsAmt>16</DisbursementsCharitablePrpsAmt>
      </OtherExpensesScheduleGrp>
      <OtherExpensesScheduleGrp>
        <Desc>BANK FEES AND SERVICE CHARGES</Desc>
        <RevenueAndExpensesPerBooksAmt>4970</RevenueAndExpensesPerBooksAmt>
        <NetInvestmentIncomeAmt>675</NetInvestmentIncomeAmt>
        <DisbursementsCharitablePrpsAmt>4295</DisbursementsCharitablePrpsAmt>
      </OtherExpensesScheduleGrp>
      <OtherExpensesScheduleGrp>
        <Desc>REGISTRATION, LICENSES, AND PERMITS</Desc>
        <RevenueAndExpensesPerBooksAmt>100</RevenueAndExpensesPerBooksAmt>
        <NetInvestmentIncomeAmt>0</NetInvestmentIncomeAmt>
        <DisbursementsCharitablePrpsAmt>100</DisbursementsCharitablePrpsAmt>
      </OtherExpensesScheduleGrp>
      <OtherExpensesScheduleGrp>
        <Desc>CHARITABLE SCIENTIFIC RESEARCH</Desc>
        <RevenueAndExpensesPerBooksAmt>150000</RevenueAndExpensesPerBooksAmt>
        <NetInvestmentIncomeAmt>0</NetInvestmentIncomeAmt>
        <DisbursementsCharitablePrpsAmt>150000</DisbursementsCharitablePrpsAmt>
      </OtherExpensesScheduleGrp>
    </OtherExpensesSchedule>
    <OtherIncreasesSchedule documentId="RetDoc2049700001">
      <OtherIncreasesDetail>
        <Desc>UNREALIZED GAIN</Desc>
        <Amt>44426</Amt>
      </OtherIncreasesDetail>
    </OtherIncreasesSchedule>
  </ReturnData>
</Return>
